KAI Pharmaceuticals

In accordance with its belief that there is an unmet need in Secondary Hyperparathyroidism [SHPT], Amgen (NASDAQ: AMGN) announced this morning that it has acquired privately held KAI Pharmaceuticals for $315M cash. J.P. Morgan commented on the merger this morning, explaining why San Francisco-...